Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM.

Cancer Discov. 2018 Oct 1. doi: 10.1158/2159-8290.CD-18-0657. [Epub ahead of print]

PMID:
30274972
2.

Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.

Rutherford SC, Fachel AA, Li S, Sawh S, Muley A, Ishii J, Saxena A, Dominguez PM, Caldas Lopes E, Agirre X, Chambwe N, Correa F, Jiang Y, Richards KL, Betel D, Shaknovich R.

Blood. 2018 Aug 16;132(7):e13-e23. doi: 10.1182/blood-2017-12-821843. Epub 2018 Jul 2.

PMID:
29967128
3.

SOX11 augments BCR signaling to drive MCL-like tumor development.

Kuo PY, Jatiani SS, Rahman AH, Edwards D, Jiang Z, Ahr K, Perumal D, Leshchenko VV, Brody J, Shaknovich R, Ye BH, Parekh S.

Blood. 2018 May 17;131(20):2247-2255. doi: 10.1182/blood-2018-02-832535. Epub 2018 Apr 3.

PMID:
29615403
4.

AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.

Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R.

Nat Commun. 2018 Jan 15;9(1):222. doi: 10.1038/s41467-017-02595-w.

5.

The new frontier of epigenetic heterogeneity in B-cell neoplasms.

Dominguez PM, Teater M, Shaknovich R.

Curr Opin Hematol. 2017 Jul;24(4):402-408. doi: 10.1097/MOH.0000000000000348. Review.

PMID:
28375986
6.

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.

Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM.

Cancer Discov. 2017 Jan;7(1):38-53. doi: 10.1158/2159-8290.CD-16-0975. Epub 2016 Oct 12.

7.

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.

Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, Hamline MY, Gascoyne RD, Levine RL, Abdel-Wahab O, Licht JD, Shaknovich R, Elemento O, Bardwell VJ, Melnick AM.

Cancer Cell. 2016 Aug 8;30(2):197-213. doi: 10.1016/j.ccell.2016.07.006.

8.

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, Abbott J, Tam W, Du W, Leonard JP, Elemento O, Cerchietti L, Cierpicki T, Xue F, MacKerell AD Jr, Melnick AM.

J Clin Invest. 2016 Sep 1;126(9):3351-62. doi: 10.1172/JCI85795. Epub 2016 Aug 2.

9.

miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.

Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS.

Blood. 2016 Jun 9;127(23):2856-66. doi: 10.1182/blood-2015-11-680462. Epub 2016 Mar 3.

10.

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.

J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.

11.

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, Hother C, Liu S, Cao XJ, Tam W, Shaknovich R, Garcia BA, Gascoyne RD, Ge K, Shilatifard A, Elemento O, Nussenzweig A, Melnick AM, Wendel HG.

Nat Med. 2015 Oct;21(10):1199-208. doi: 10.1038/nm.3943. Epub 2015 Sep 14.

12.

DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID.

Dominguez PM, Teater M, Chambwe N, Kormaksson M, Redmond D, Ishii J, Vuong B, Chaudhuri J, Melnick A, Vasanthakumar A, Godley LA, Papavasiliou FN, Elemento O, Shaknovich R.

Cell Rep. 2015 Sep 29;12(12):2086-98. doi: 10.1016/j.celrep.2015.08.036. Epub 2015 Sep 10.

13.

Erratum: TET1 is a tumor suppressor of hematopoietic malignancy.

Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma AK, Jaenisch R, Aifantis I.

Nat Immunol. 2015 Aug;16(8):889. doi: 10.1038/ni0815-889a. No abstract available.

PMID:
26194287
14.

Signatures of accelerated somatic evolution in gene promoters in multiple cancer types.

Smith KS, Yadav VK, Pedersen BS, Shaknovich R, Geraci MW, Pollard KS, De S.

Nucleic Acids Res. 2015 Jun 23;43(11):5307-17. doi: 10.1093/nar/gkv419. Epub 2015 May 1.

15.

Epigenomic evolution in diffuse large B-cell lymphomas.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R, Melnick AM, Inghirami GG, Tam W, Elemento O.

Nat Commun. 2015 Apr 20;6:6921. doi: 10.1038/ncomms7921.

16.

TET1 is a tumor suppressor of hematopoietic malignancy.

Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma AK, Jaenisch R, Aifantis I.

Nat Immunol. 2015 Jun;16(6):653-62. doi: 10.1038/ni.3148. Epub 2015 Apr 13. Erratum in: Nat Immunol. 2015 Aug;16(8):889.

17.

IL10 receptor is a novel therapeutic target in DLBCLs.

Béguelin W, Sawh S, Chambwe N, Chan FC, Jiang Y, Choo JW, Scott DW, Chalmers A, Geng H, Tsikitas L, Tam W, Bhagat G, Gascoyne RD, Shaknovich R.

Leukemia. 2015 Aug;29(8):1684-94. doi: 10.1038/leu.2015.57. Epub 2015 Mar 3.

PMID:
25733167
18.

Epigenetic function of activation-induced cytidine deaminase and its link to lymphomagenesis.

Dominguez PM, Shaknovich R.

Front Immunol. 2014 Dec 18;5:642. doi: 10.3389/fimmu.2014.00642. eCollection 2014. Review.

19.

Epigenetic diversity in hematopoietic neoplasms.

Shaknovich R, De S, Michor F.

Biochim Biophys Acta. 2014 Dec;1846(2):477-84. doi: 10.1016/j.bbcan.2014.09.003. Epub 2014 Sep 18. Review.

PMID:
25240947
20.

CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer.

Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, Filippova GN.

Cell Rep. 2014 May 22;7(4):1020-9. doi: 10.1016/j.celrep.2014.04.004. Epub 2014 May 1.

21.

Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development.

Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang Y, Lehrmann E, Becker KG, Shaknovich R, Liu Z, Gartenhaus RB.

PLoS Genet. 2014 Jan 30;10(1):e1004105. doi: 10.1371/journal.pgen.1004105. eCollection 2014 Jan.

22.

Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.

Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R.

Blood. 2014 Mar 13;123(11):1699-708. doi: 10.1182/blood-2013-07-509885. Epub 2014 Jan 2.

23.

Gene expression and epigenetic deregulation.

Shaknovich R.

Adv Exp Med Biol. 2013;792:133-50. doi: 10.1007/978-1-4614-8051-8_6. Review.

PMID:
24014295
24.

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L.

Cancer Discov. 2013 Sep;3(9):1002-19. doi: 10.1158/2159-8290.CD-13-0117. Epub 2013 Aug 16.

25.

GobyWeb: simplified management and analysis of gene expression and DNA methylation sequencing data.

Dorff KC, Chambwe N, Zeno Z, Simi M, Shaknovich R, Campagne F.

PLoS One. 2013 Jul 23;8(7):e69666. doi: 10.1371/journal.pone.0069666. Print 2013.

26.

Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Jiang Y, Hatzi K, Shaknovich R.

Blood. 2013 May 23;121(21):4271-9. doi: 10.1182/blood-2012-12-451799. Review. No abstract available.

27.

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM.

Cancer Cell. 2013 May 13;23(5):677-92. doi: 10.1016/j.ccr.2013.04.011.

28.

Downregulation of FOXP1 is required during germinal center B-cell function.

Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MA, Elemento O, Shaknovich R, Fontán L, Fresquet V, Perez-Roger I, Robles EF, De Smedt L, Sagaert X, Melnick A, Martinez-Climent JA.

Blood. 2013 May 23;121(21):4311-20. doi: 10.1182/blood-2012-10-462846. Epub 2013 Apr 11.

29.

Differential gene body methylation and reduced expression of cell adhesion and neurotransmitter receptor genes in adverse maternal environment.

Oh JE, Chambwe N, Klein S, Gal J, Andrews S, Gleason G, Shaknovich R, Melnick A, Campagne F, Toth M.

Transl Psychiatry. 2013 Jan 22;3:e218. doi: 10.1038/tp.2012.130.

30.

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F.

PLoS Genet. 2013;9(1):e1003137. doi: 10.1371/journal.pgen.1003137. Epub 2013 Jan 10.

31.

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick A.

Cancer Cell. 2012 Dec 11;22(6):812-24. doi: 10.1016/j.ccr.2012.11.003.

32.

Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.

Ouillette P, Li J, Shaknovich R, Li Y, Melnick A, Shedden K, Malek SN.

Genes Chromosomes Cancer. 2012 Dec;51(12):1125-32. doi: 10.1002/gcc.21997. Epub 2012 Sep 6.

33.

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG.

Cell. 2011 Oct 28;147(3):554-64. doi: 10.1016/j.cell.2011.09.035.

34.

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL.

Blood. 2011 Dec 8;118(24):6342-52. doi: 10.1182/blood-2011-02-333773. Epub 2011 Oct 24.

35.

DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.

Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, Godley LA, Michor F, Elemento O, Melnick A.

Blood. 2011 Sep 29;118(13):3559-69. doi: 10.1182/blood-2011-06-357996. Epub 2011 Aug 9.

36.

Epigenetics and B-cell lymphoma.

Shaknovich R, Melnick A.

Curr Opin Hematol. 2011 Jul;18(4):293-9. doi: 10.1097/MOH.0b013e32834788cf. Review.

37.

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A.

J Clin Invest. 2010 Dec 1;120(12):4569-82. doi: 10.1172/JCI42869. Epub 2010 Nov 1.

38.

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O.

Blood. 2010 Dec 9;116(24):5247-55. doi: 10.1182/blood-2010-04-280149. Epub 2010 Aug 24.

39.

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.

Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A.

Blood. 2010 Nov 18;116(20):e81-9. doi: 10.1182/blood-2010-05-285320. Epub 2010 Jul 7.

40.

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S.

Blood. 2010 Aug 19;116(7):1025-34. doi: 10.1182/blood-2009-12-257485. Epub 2010 Apr 28.

41.

Requirement for cyclin D3 in germinal center formation and function.

Peled JU, Yu JJ, Venkatesh J, Bi E, Ding BB, Krupski-Downs M, Shaknovich R, Sicinski P, Diamond B, Scharff MD, Ye BH.

Cell Res. 2010 Jun;20(6):631-46. doi: 10.1038/cr.2010.55. Epub 2010 Apr 20.

42.

HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes.

Shaknovich R, Figueroa ME, Melnick A.

Methods Mol Biol. 2010;632:191-201. doi: 10.1007/978-1-60761-663-4_12.

PMID:
20217579
43.

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A.

Nat Med. 2009 Dec;15(12):1369-76. doi: 10.1038/nm.2059. Epub 2009 Nov 22.

44.

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O, Melnick A.

Blood. 2009 May 28;113(22):5536-48. doi: 10.1182/blood-2008-12-193037. Epub 2009 Mar 23.

45.

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.

Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.

Blood. 2009 Apr 9;113(15):3397-405. doi: 10.1182/blood-2008-07-168773. Epub 2008 Oct 16.

46.

Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.

Cancer Res. 2008 May 1;68(9):3361-9. doi: 10.1158/0008-5472.CAN-07-5817.

47.

Oncogenic viruses in AIDS: mechanisms of disease and intrathoracic manifestations.

Burns J, Shaknovich R, Lau J, Haramati LB.

AJR Am J Roentgenol. 2007 Nov;189(5):1082-7. Review.

PMID:
17954644
48.

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH.

Blood. 2008 Feb 1;111(3):1515-23. Epub 2007 Oct 19.

49.

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A.

Blood. 2007 Sep 15;110(6):2067-74. Epub 2007 Jun 1.

50.

Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance.

Cattoretti G, Shaknovich R, Smith PM, Jäck HM, Murty VV, Alobeid B.

J Immunol. 2006 Nov 15;177(10):6930-9.

Supplemental Content

Loading ...
Support Center